2seventy bio (TSVT) Announces Key Milestones and Business Updates for 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
2seventy bio Shares Key Milestones and Business Updates for 2022
January 11, 2022 7:00 AM ESTABECMA generated approximately $150M U.S. revenue in 2021, equally shared by 2seventy bio and Bristol Myers Squibb; anticipate continued ABECMA growth in 2022 with $250-300M U.S. revenue
bbT369 IND cleared - program tests three layers of innovation in B-NHL; achieved goal of two new INDs submitted and cleared by FDA in 2021; patient enrollment underway in studies in B-NHL and AML
New solid tumor CAR T program targeting MUC16 unveiled
Ended 2021 with approximately $360M cash, anticipate reduced net cash spend... More
